Clinical trials · San Francisco, CA
Non Small Cell Lung Cancer clinical trials in San Francisco
We’re tracking 84 recruiting non small cell lung cancer studies with a site in or near San Francisco — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near San Francisco
- NCT04165070RecruitingPhase 1/Phase 2
Stage IV lung cancer trial using pembrolizumab with or without chemotherapy
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
San Francisco, CaliforniaAges 18 years+ - NCT04510129Recruiting
Cancer biospecimen collection study for immunotherapy patients
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
San Francisco, CaliforniaAges 18 years+ - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
San Francisco, CaliforniaAges 18 years+ - NCT04165798Recruiting
Pembrolizumab with or without chemotherapy for stage IV lung cancer
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
San Francisco, CaliforniaAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
San Francisco, CaliforniaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Francisco, CaliforniaAges 18 years+ - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
San Francisco, CaliforniaAges 16 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
San Francisco, CaliforniaAges 18 years+ - NCT06418204Recruiting
Cannabis use study for cancer patients in community clinics
This study looks at the benefits and risks of using cannabis or cannabinoids for cancer patients. It aims to help understand how these products affect symptoms and quality of life during chemotherapy or immunotherapy.
San Francisco, CaliforniaAges 18 years+ - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
San Francisco, CaliforniaAges 18 years+ - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT06116682RecruitingPhase 2
Targeted treatment for MET-positive advanced lung cancer
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
San Francisco, CaliforniaAges 18 years+ - NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
San Francisco, CaliforniaAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
San Francisco, CaliforniaAges 18 years+ - NCT07491497RecruitingPhase 1/Phase 2
Study of TRI-611 for ALK-positive lung cancer
This trial tests a new investigational drug called TRI-611 for people with ALK-positive non-small cell lung cancer. It is designed for people who have already tried other ALK-targeted medicines, especially lorlatinib, and whose cancer may have stopped responding to them.
San Francisco, CaliforniaAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT04267848RecruitingPhase 3
Testing immunotherapy with chemo after lung cancer surgery
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
San Francisco, CaliforniaAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
San Francisco, CaliforniaAges 18 years+ - NCT06632327RecruitingPhase 3
Comparing treatment timing for stage II-IIIB lung cancer
This trial is for people with a certain type of lung cancer (non-small cell lung cancer) that can be surgically removed. It tests whether it is better to receive treatment before or after surgery to remove the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
San Francisco, CaliforniaAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
San Francisco, CaliforniaAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
San Francisco, CaliforniaAges 18 years+ - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
San Francisco, CaliforniaAges 18 years+
Hear when a new Non Small Cell Lung Cancer trial opens near San Francisco, CA
We’ll email you when one opens near San Francisco, CA — at most once a week, no account needed, unsubscribe anytime.
Non Small Cell Lung Cancer trials in other cities
Where these studies are running near San Francisco
Institutions with a site for the recruiting non small cell lung cancer studies listed above.
- University of California, San Francisco · 14 studies
- Kaiser Permanente-Vallejo · 5 studies
- Kaiser Permanente Medical Center - Santa Clara · 4 studies
- Kaiser Permanente San Leandro · 4 studies
- Kaiser Permanente San Rafael · 4 studies
- Kaiser Permanente-Oakland · 4 studies
- Kaiser Permanente-San Francisco · 4 studies
- Kaiser Permanente-Santa Teresa-San Jose · 4 studies
What taking part in a non small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting non small cell lung cancer studies in California.
Common questions
- Are there non small cell lung cancer clinical trials near San Francisco?
- Yes. We're currently tracking 84 recruiting non small cell lung cancer studies with a site near San Francisco, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non small cell lung cancer study near San Francisco?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in San Francisco to take part?
- Not necessarily. These studies have a site near San Francisco, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non small cell lung cancer studies open near San Francisco regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.